128 Nanomedicine/Nanotechnology Companies - Worldwide

Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company developing precision therapies for genetically-defined cancers.

Acuitas is the premier LNP (lipid nanoparticle) technology provider, enabling our partners to advance new therapeutics to address unmet clinical needs. We have developed a broad IP portfolio focussed on the use of LNP technology for nucleic acid therapeutics. This portfolio primarily encompasses novel compositions of matter but also includes novel uses of nucleic acids therapeutics. Our mission is · To provide our partners with the best LNP delivery technology for nucleic acid therapeutics · To support our partners to rapidly advance new therapeutics to address unmet medical needs · To continually innovate to maintain and strengthen our LNP technological lead Acuitas partners locally and globally with companies, academic institutes and other organizations to improve human health.

Adipo Therapeutics, an Indiana biotechnology company, is developing polymer-based, Notch-inhibiting nanoparticles that are injected directly into adipose (fat) tissue to induce browning, or white-to-beige adipocyte transformation. The goal? Reducing weight and restoring metabolic balance for millions of people living with diabetes.

Aera was founded with a vision to unlock the potential of genetic medicines across a broad range of modalities and therapeutic areas. Our protein nanoparticle (PNP) delivery platform leverages the discovery of endogenous, human proteins that can self-assemble to form capsid-like structures and that can package and transfer nucleic acid cargo. This platform has the potential to address many of the limitations of today’s delivery technologies and to enable various genetic medicine modalities.

At Alaya.bio, we're developing a revolutionary targeting polymeric nanoparticle that enhances the transduction efficiency of quiescent cells such as T-cells, NK-cells, and stem cells. Our platform eliminates the need for activation factors or cytokines, resulting in reduced exhaustion of transduced cells while preserving their naive and memory phenotypes, leading to better clinical outcomes.

Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Alnylam is turning scientific possibility into reality - in 2018, the FDA and EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. We now have three additional medicines on the market: GIVLAARI (givosiran), OXLUMO (lumasiran) and LEQVIO (inclisiran) in partnership with Novartis). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,700 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer 3 years in a row ('19-'21), a Boston Globe Top Place to Work 7x in a row ('15-'21) and one of Fast Company's Best Workplaces for Innovators for 2021.

Applied NanoStructures is a premier supplier of AFM and SPM Probes as well as custom MEMS devices. The AppNano state-of-the-art MEMs foundry is located in the heart of silicon valley. The company was founded by Dr. Ami Chand who has worked in the NanoTechnology area for more than 20 years.

Apurun specializes in tech transfer development and GMP manufacturing services for nanoparticle pharmaceuticals and nanomedicines. Their comprehensive approach enables and supports the development of nanoparticle pharmaceuticals.

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed Kostaive®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries).

Ardena is a pharmaceutical CDMO that guides companies through the drug discovery and development process to help create effective and compliant drug substance and products for clinical trials. Ardena provides you with an integrated service offering including solid state chemistry, API & nanomedicines development and manufacturing, analytical & formulation development, drug product manufacturing, bioanalytical, drug discovery and dossier development services. Headquartered in Ghent, we have facilities in the Netherlands, Belgium, Sweden and Spain, serving a global customer base, ranging from emerging biotech to tier-one pharmaceutical companies. We understand the complex challenges involved in taking a promising molecule from lab to patient. Each project we undertake is preceded by a detailed planning phase to ensure that the right work is carried out at the right time. This staged approach allows you to stagger your investments and mitigate risks during each phase of the project. Our integrated offering is the engine that drives all of our projects. Our multidisciplinary team is keen to streamline your development process. We also make sure that all the work we do for you is compliant with the appropriate regulatory standards as you move along the clinical development path. Our dossier-centric approach is key to help you compile your regulatory dossier in a timely and cost-efficient manner. By preparing your regulatory dossier in parallel with drug development, we ultimately get your drug to patients faster.

Arrow Dx is combining Nanotechnology and Artificial Intelligence (AI) to create an inexpensive, sensitive test to screen early for non-alcoholic fatty liver disease (NAFLD). Our aim is to provide physicians with an alternative to liver biopsy which detects the disease too late. We are working to solve the lack of rapid, reliable, point-of-care, and inexpensive diagnostic devices by bring faster, inexpensive and mobile testing for many other applications that require a rapid response (e.g., epidemic/pandemics, public health crisis, early diagnosis for rising complex non-communicable diseases, testing in emergency rooms). Our technology makes it more affordable for smaller healthcare providers such as Physician Office Labs (~100,000 in the U.S.), independent physicians and public health workers to access diagnostics due to our significantly lower cost as well as our portable, small compact size. Finally, we are also working to create a test for COVID-19 as well as other viruses, initially quantifying the virus in wastewater to help public health authorities and later to detect it in biological samples from individuals and patients.

ARTIDIS AG is a clinical stage medical technology company developing the first nanotechnology platform for tissue analysis combined with a digital data platform, intended for broad use in drug discovery, tissue engineering as well as for rapid diagnostics and personalized treatment optimization.

Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs), which link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. We believe this approach to precision medicine has the potential to change the standard of care across neurology, ophthalmology, hyperinflammatory diseases and neuro-oncology.

Developing seamless neural interfaces.

BioCurity Pharmaceuticals Inc. (“BioCurity”), is a biopharmaceutical company with a mission to positively transform radiation therapy for cancer patients, by addressing the global unmet need for an effective treatment to prevent toxicity from radiation therapy (radiation dermatitis). Approximately 6 million of the 18 million people who will be diagnosed with cancer every year, will receive radiation treatment. The lack of an effective treatment for the adverse side effects associated with radiation therapy represents a substantial market opportunity, but most importantly, a chance to help better the quality of life for cancer survivors around the world. BioCurity’s patented technologies and drugs in their pipeline have the potential to significantly reduce radiation toxicity for newly diagnosed patients as well as the millions of cancer patients who continue to receive radiation as a part of their ongoing treatment for cancer.

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma and diffuse midline glioma. MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and avoiding systemic toxicity.

BioForce Nanosciences, Inc. develops and commercializes nanotech instruments, consumables, and applications for the life sciences. For over a decade we've been a leading provider of consumable support products for atomic force microscopy (AFM). In 2005 we introduced our own flagship instrument platform, the Nano eNabler™ system. The Nano eNabler system is a molecular printer that rapidly and precisely delivers liquids to surfaces such as silicon chips in droplets that are ten billion times smaller than a drop of blood. This unique capability offers researchers in industry and academia a practical solution to problems they encounter when developing ultraminiaturized devices and methods, and creates opportunities for further commercialization of nanotechnology. For example, BioForce’s technology is being used to create biosensors and to study cell biology at the single cell level. Additional applications include printing proteins to guide neural cell growth, printing signaling proteins to study stem cell differentiation, “inking” of micro-stamps for soft lithography, and bio-functionalization of microfluidic devices.

BIORCHESTRA is an innovative biotech company focusing on research and development of ribonucleic acid (RNA) based therapeutics. Our goal is to change the therapeutic paradigm from treating the symptoms to providing fundamental cure of the diseases. As we are making steady progress in the clinical development, we seek global partners to collaborate in the areas of research and development (R&D) and the commercialization.

BioTechnique is a contract manufacturing organization that provides standard and highly-customized cytotoxic and high potency sterile injectable liquid & lyophilized fill-finish services. Our state-of-the-art manufacturing facility is also equipped with a full-scale microbiology lab and offers regulatory affairs, laboratory, and project management support from investigational/clinical all the way through phase IV/commercial. Facility Capabilities: • Sterile injectable manufacturing & packaging for liquid & lyophilized products • Aseptic Vial Filling • Aseptic Lyophilization • Inspection • Formulation • Product Testing • Labeling/Packaging • Stability Storage • Process Design • Full service laboratory • Regulatory affairs support for product filings • Project management Product Capabilities: • Cytotoxics • Highly-Potent Compounds • Monoclonal Antibodies • Antibody Drug Conjugates (ADC) • Suspensions • Inactivated & Attenuated Live Vaccines Filling & Manufacturing Capabilities: • Grade A / ISO 5 Aseptic Filling Suite • 2mL to 100mL vials • 0.2mL to 100mL fill volume • Inline fill volume check weighing • Isolator • 13M2 Lyophilizer • Containment Unloading • Grade A / ISO 5 Capping • Post-Fill / Post-Lyo External Vial Rinse • Single-Use Disposable Manufacturing Train • Vial Inspection & Labeling • ICH Guideline Cold Storage • 2 to 8 ℃ • -20 to -70 ℃ • Stability Chambers & Warehouse Storage • Microbiology & Chemistry Labs

Developing new drugs under FDA regulation for hypoxia brain and heart ischemia and viral infection like coronavirus and influenza.

Clene Inc., a clinical-stage biopharmaceutical company, focuses on the development of various therapeutics for neurodegenerative diseases. The company has a nanotechnology drug platform for the development of orally administered neurotherapeutic drugs. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson’s; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company’s products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; and NM-PtAu7, a gold-platinum CSN therapeutic. Clene Inc. is based in Salt Lake City, Utah.

COARE Biotechnology is a multidisciplinary drug development company that seeks to advance the current treatment modality of patients with aggressive cancers by coordinately targeting aspects of both the primary tumor and the biological processes that effect metastatic initiation and progression. Our team has garnered worldwide acclaim for their groundbreaking scientific discoveries in support of the novel therapeutic platforms developed here at COARE Biotechnology. We have identified key components within cancer biology that have not been targeted – until now.

Coastar Therapeutics is a pre-clinical biotech company developing biological payload delivery technologies for cancer immunotherapy and gene therapies. Our proprietary ENHEnS technology can be used to coat biological payloads with cell membranes, which help them evade recognition and clearance by the immune system and be successfully delivered to tumor or other disease sites.

We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to a variety of diseases. By attacking the disease directly with our novel nanoparticle-based technologies and working strategically with our medical and scientific partners we seek to provide treatments and cures previously unavailable to doctors and their patients.

Cytodiagnostics is a biotechnology and diagnostics company based in Burlington, ON, Canada, and Tulsa, OK, USA, and a Research and Development Position at the Innovate Calgary Life Science Hub at the University of Calgary. Over the past fifteen years, Cytodiagnostics has become the pre-eminent global supplier of gold and silver nanoparticles. With a commitment to providing quality materials, our in-depth knowledge of particle behaviour spans from initial synthesis to chemical functionalization and detection molecule conjugation, giving us a unique advantage for incorporating nanoparticles into diagnostic tests. This realization led to the creation of CytoGROUP, a branch of our business with the mission of using excellent materials to provide top-notch lab-based and point-of-care diagnostics. Our team has applied their expertise with chemical modifications as well as antibody and cutting-edge nucleic acid/aptamer detection molecules to create a range of products from lateral flow tests to plate-based assays, along with custom diagnostic test development services. In addition to our two locations, Cytodiagnostics also has an associate company, CytoGroup, which specializes in lateral flow and vertical flow assays, ELISA, ELASA and Aptamer Development. Both products and development services are available. Our goal is to serve our customers with the highest quality products to ensure success in their research and development efforts.

DelSiTech is a drug delivery and drug development company based in Turku, Finland. DelSiTech has developed a unique proprietary technology making it a world leader in advanced biodegradable silica-based drug delivery. The technology has successfully been applied to the controlled release of small molecules, biopharmaceuticals and viral vectors with a focus on parenteral and local administration. We can work with you from early feasibility testing to clinical proof of concept; the technology can also be licensed to industry partners. With the DelSiTechTMSilica Matrix, we can create novel products, provide alternative administration opportunities, and extend and manage the life cycle of existing products. More patient-friendly products can be developed which release active compounds over days to many months. The technology is also well suited for challenging drug delivery needs such as controlled local delivery to the eye or the brain. At DelSiTech, we are also developing our own in-house supergeneric drug products for significant unmet medical and market needs. Our lead product, 1308, is a 3 month subcutaneous product for hepatitis B. 1308 will enter clinical studies in Q1 2017.

Direct Electron designs, manufactures, and delivers next-generation direct detection cameras for electron microscopy. Our vision—Innovation Propelling Discovery—is focused on empowering our customers to efficiently and continually expand the frontiers of science. Our approach involves: (1) A strong commitment to research and development that enables us to continually offer new technological innovations, (2) Unique features to improve efficiency in data collection and processing, and (3) A collaborative culture with exceptional customer service and support.

DNP123 is a startup focused on solving nanotech manufacturing problems. We work with industry, government labs, and academic research groups to enable the design and assembly of novel nanotech devices. DNP123’s patent-pending core IP—DNA-patched nanocubes that self-assemble designable structures—affords a simple, standardized method of assembling almost any three-dimensional structure at nanoscale.

Doty Scientific, Inc. was founded by Dr. F. David Doty (president and chief engineering scientist) in May 1982, in Columbia, South Carolina, for the primary purpose of designing and manufacturing scientific instrumentation. The company’s initial product was a CP/MAS (Cross Polarization/Magic Angle Spinning) probe for chemical structure determination of solid materials via Nuclear Magnetic Reso­nance (NMR).

Duo Oncology, founded by oncologists, is developing tumor-penetrating nanomedicines to upgraded the foundations of cancer medicine. Duo's patented platform prodrug chemistry releases creates nanomedicines that penetrate established tumors to reduce toxicity and improve patient outcomes.

Based on DNA nanotechnology, our novel family of Janus base nanomaterials provides highly effective, super biocompatible solutions that enable enhanced therapeutic delivery and regenerative medicine for articular cartilage, central nervous system disorders, solid tumors, and other chronic conditions. Our three generations of DNA-inspired nanotubes are a cost-effective alternative to existing options, and they have excellent scalability. We can customize our Janus base nanotechnologies to enhance the therapeutic efficacy of drug treatments for a variety of chronic conditions and medical needs.

Advancing regenerative medicine through the development of a natural biomaterial that restores mother nature’s template to treat disease and injury. ECM scaffolds, in solid form, have been successfully used in more than 10 million human patients to repair a variety of body systems such as musculoskeletal tissues, cardiovascular structures, and non-healing skin wounds, among others. These products have all received FDA clearance. ECM Therapeutics'​ patented ECM hydrogel technology allows for expanded, less invasive applications in multiple disease areas. The first clinical product, EsophaGel, treats Barrett’s esophagus, a precancerous condition that currently has no effective therapy.

Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice. Our team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting.

Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing.

Ellume is an Australian based Health Technology company that develops and manufactures connected real-time diagnostics for doctors and consumers. We achieve this by combining next-generation quantum dot diagnostics with connected care technologies. Our products are distinguished by their simplicity of design, ease of use, rapid time to result and connectivity. To learn more about Ellume, visit our website at www.ellumehealth.com.

Elucida Oncology is a biotechnology company that pioneers targeted cancer therapy with ultra-small nanoparticle C’Dot drug conjugates designed to penetrate deep into tumors.

Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biotech company developing a new class of prescription drugs that will provide patients and prescribers safer options for the use of potent prescription drugs, reducing abuse and preventing overdoses.

Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company. A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion.

Esphera SynBio is developing next-generation cancer and immunoregulatory treatments through its innovative synthetic biology platform. The company develops advanced nanomedicines in the form of functionalized vesicles, which can be produced either in vitro or in vivo through their proprietary transgene technology. Esphera’s lead clinical candidate represents a novel approach in cancer immunotherapy - an off-the-shelf treatment that triggers tumor cells to generate a bespoke personalized cancer vaccine in vivo. Beyond oncology, Esphera's versatile platform shows promise in broader immunomodulation applications.

Exavir Therapeutics is a biotechnology company dedicated to developing nanomedicines for chronic disorders in virology and CNS, beginning with ultra-long-acting integrase inhibitors for HIV Treatment and HIV PrEP.

Advancing the Science of exosomes and precision Growth Factors, Exocel Bio strives to be the leader in the regenerative aesthetic industry by leveraging our nanoparticle technology platform, and is dedicated to the pursuit of making anti-aging a reality. EXOVEX is a skin post Laser or Microneedling treatment packed with exosomes and precision growth factors that have been formulated to accelerate recovery and enhance efficacy by improving the appearance of hair, fine lines, wrinkles, skin tone and texture.

At Eyam, our mission is to bring “Next Generation” vaccine and therapeutic technologies to market to solve today's health care needs.

The mission of Foothold Labs is to develop a next generation rapid diagnostic platform for point of care healthcare applications. Our NanoRev System uses artificial intelligence enabled electrochemical biosensors to rapidly detect infectious disease related biomarkers in saliva in five minutes for under $35 per test. We have partnerships with the Naval Research Laboratory, MIT Chemistry, and the University of Kansas Bioengineering program. Additionally, we have captured more than $1.5MM in SBIR grant funding from the US Air Force and US Special Operations Command over the last twelve months. (As of May 2022)

GenEdit is revolutionizing genetic medicines by developing innovative therapies through targeted delivery of genetic medicines.

Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts.

Genovis offers a unique range of rapid and easy to use enzymatic tools primarily for the biopharmaceutical industry. Available worldwide, these SmartEnzymes™ are supplied in innovative formats for the development, production and quality control of biological drugs such as monoclonal antibodies, ADCs, biosimilars and bispecifics. The Genovis SmartEnzymes are widely used for the digestion, de-glycosylation and conjugation of the target molecule and are an ideal companion to popular analytical techniques like LC-MS. Within the portfolio there are enzymes specific for: IgG digestion - FabRICATOR™, FabALACTICA™, GingisKHAN™, FabULOUS™ & FabRICATOR Z™ General proteolysis - GingisREX™ De-glycosylation and conjugation of IgGs - GlycINATOR™, IgGZERO™ and GlyCLICK™ O-glycan analysis - OglyZOR™, OpeRATOR™, GlycOCATCH™ and SialEXO™

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the body. The Company’s lead product candidate, REQORSA® (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Both NSCLC clinical programs received a Fast Track Designation from the Food and Drug Administration. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

HDT Bio is a vaccine and immunotherapy Biotechnology company developing drugs for immunotherapy of cancers and infectious diseases with next-generation approaches designed to enable the body’s immune system to prevent and cure disease. We have engineered our technologies to Access, Activate, and Amplify the immune system’s natural ability to create antibodies and T-cells that fight cancer and infectious diseases such as SARS-CoV-2. We are developing multiple product candidates from our proprietary discovery platforms, including LION™, which has the potential to provide health benefits to a broad patient population. Our products are designed to be cost-effective solutions to unmet medical needs and complementary to existing, cutting-edge immunotherapies. HDT Bio offers a comprehensive compensation plan which includes health insurance for employees and dependents (inclusive of multiple plants to choose from, including a $0 premium plan with HSA and company contribution), generous PTO (11 observed holidays and week long year-end closure), stock options with Carta Tax Advisory for equity and tax support, flexible spending accounts (FSAs), commuting benefits (ORCA or paid parking), and retirement benefits with company match. HDT Bio Corp. is an equal opportunity employer committed to a diverse and inclusive workforce. This environment is encouraged by HDT's culture, which supports women in science through our Women+ group, creates inclusive events to highlight the diverse cultures represented by our staff, and with the adoption of an open office environment for all.

Hopewell Therapeutics is discovering, synthesizing and developing the next generation of tissue-targeted lipid nanoparticles (ttLNPs) to bring genomic medicines to patients. We are pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. Hopewell has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry leading companies. We are developing our own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of our ttLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases and neurological disorders.

Imagion Biosystems is dedicated to providing tools to find and eliminate cancer. We are a multidisciplinary team with expertise in the physics of magnetic fields and nanotechnology and the medical application of these fields. Our focus is in the rapidly emerging field of nanobiotechnology with an emphasis on the early detection and localization of cancer and other human diseases. Our technologies also hold the promise of providing image-guided therapy for the treatment of these diseases, as well as providing new methods for therapeutic intervention. Our proprietary technologies and methods employ magnetic nanoparticles targeted towards cells associated with cancer and other diseases and provide the ability to detect these cells using highly sensitive magnetic sensors. These methods have numerous preclinical and clinical applications. Preclinical research projects have focused on the early detection of breast cancer, ovarian cancer, and prostate cancer.

Immunyx Pharma is focused on changing the landscape of immune modulation by targeting neutrophil toxicity in numerous chronic diseases. The company was built by world leaders in neutrophil biology and nanoparticle delivery to use a targeted neutrophil nanoparticle platform (TENNs) to solve the significant issues in neutrophil therapy. While big pharma has invested heavily in neutrophil targeted drugs, they have failed to bring solutions to the clinic due to the danger of causing neutropenia and the difficulty of modulating such a large & dynamic population of cells. Our TENN platform is intended to manipulate neutrophil toxic behavior without destroying their disease fighting function, while bringing a concentrated payload of drug to all neutrophils throughout the body with a long bioavailability. We are currently focusing on applying our platform to modulate neutrophil activity in cancer and inflammatory disease.

INanoBio’s mission is to develop high-accuracy early stage disease diagnostics using transformative nano-biotechnology platforms and machine learning. Extract systems scale information from complex disease biology, identify and detect disease specific molecular biomarkers, signatures at prodromal or pre-symptomatic stages. We believe most diseases can be detected early, enabling early personalized therapeutic intervention to preempt full development of diseases, ushering in preemptive medicine.

InnoUp is a clinical-stage nanotechnology company focused on developing safer and more effective treatments for Food Allergies, Oncology, and Vaccines. We have developed a new drug encapsulation platform currently being tested in different clinical and pre-clinical programs. INP20 - Oral Peanut Allergy Vaccine: Phase I INP12 - Low-toxicity Paclitaxel oral chemotherapy for Breast Cancer: Phase I INP30 - Oral Vaccine Infectious Diseases: pre-clinical Our encapsulation platform is based on biocompatible nanoparticles that allow all types of payloads (drugs, proteins, RNA, and DNA). These nanoparticles have been engineered to increase bio-adhesion capacity to the mucosa, which translates into a need for lower and safer drug doses to achieve a therapeutic effect. Therefore, drugs encapsulated using our platform become more effective and safer. The technology is protected worldwide, including USA and Europe, until 2035. Our short-term business strategy includes starting operations in the US beginning 2022 with the opening of an affiliate in Boston, MA. From there, we will manage the movement to the next phases of our clinical programs (Phase II) in the US. We are already working with the FDA for the pre-IND meeting preparation. We plan to increase our value in the mid-term by building a clinical-stage multi-asset pipeline with expected significant efficacy and safety milestones by 2025. Besides, we plan to build our GMP manufacturing facility to control our manufacturing process fully. We expect it to be fully operative by 2025. We are actively working on raising money to cover the following steps and, we are open to considering all types of investment. In parallel, we are also actively seeking licensing partners interested in our products.

Integral Molecular is a research-driven biotechnology company specializing in antibodies, viruses, and membrane proteins. We develop technologies for solving big scientific challenges and advancing therapies against difficult-to-treat diseases. Our products, platforms, and services enable antibody discovery, biotherapeutic safety profiling, vaccine development, protein engineering, and more. Learn why top pharmaceutical and biotechnology companies trust Integral Molecular. Instagram: IntegralMolecular

Ligandal is a genetic medicine company that uses nanotechnology to develop targeted and personalised therapies. As a regenerative medicine biotechnology company, Ligandal develops ultra-rapid therapeutics and vaccines for outbreaks and pandemics, in addition to its work in immuno-oncology and rare genetic diseases. Our current focus is on delivering a peptide-based cure to the COVID-19 pandemic (SARS-CoV-2 coronavirus), as part of a broader mission of enabling personalized medicine on a global scale through the power of nanomedicine and gene therapies. Given that increasingly complex disease states require precise and custom-tailored medicine, much of our technology development has focused on combining gene therapy with targeting peptides to enable completely new paradigms in evolutionary medicine. Currently, we are utilizing a peptide nanoscaffold based approach for treating COVID-19 without a gene therapy component, with the goal of creating a combined antidote-vaccine. My expertise lies in targeted gene delivery, nano- and biomaterials, computational modeling of peptides, binding simulations, immunoengineering, as well as CRISPR and TALEN based gene editing. At Ligandal, we have demonstrated peptide-based delivery of CRISPR, RNA, DNA, siRNA, and a range of genes or proteins to virtually any cell type.

Ligo Analytics, Inc. is a Texas startup that develops software for macromolecule structure determination using cryo-electron microscopy (cryo-EM).

Liquidia Technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. Our proprietary PRINT technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. PRINT technology is a scalable cGMP compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. Liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. Liquidia is advancing product candidates from its own pipeline. These initial product candidates, LIQ861 and LIQ865, apply the PRINT technology to better drug delivery in inhaled and pain therapeutic areas, respectively. The PRINT technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.

We specialise in medical technology for digital pathology and aim to improve tissue diagnostics with our patented technology. With technology based on up-converted nanoparticles (UCNP), high-quality images are generated with increased contrast and decreased irrelevant background noise. These images shorten turnaround time and provide higher-quality data for analysis. Lumito is a spin-off from a research team at Lund University's Division of Atomic Physics and Laser Centre and is planning to launch its product SCIZYS for research laboratories initially.

Magnetic Insight is developing solutions in Magnetic Particle Imaging (MPI), a new imaging modality that directly detects iron oxide nanoparticle tracers using time-varying magnetic fields. Because the tracer is not normally found in the body, MPI images have exceptional contrast and high sensitivity.

Matexcel is a service provider in materials science, with years of commitment to supply better polymers, nanoparticles and other materials for worldwide customers from both academia and industry. They offer a full range of materials covering polymers, metals, ceramics and natural materials, in addition to professional consultation service in manufacturing and characterization. Our experienced team of scientists have mastered a wide spectrum of technologies to solve interdisciplinary tasks such as custom synthesizing and developing polymeric and nano-bio applications. They are a customer-oriented company aiming to deliver product and service to the global pharmaceutical and nano-biotechnology markets.

Matinas BioPharma (NYSE AMER: MTNB) is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. The Company is developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop novel formulations that capitalize on the unique characteristics of the LNC platform. Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the challenges in achieving safe and effective intracellular delivery, for both small molecules and larger, more complex molecules, such as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines. The combination of a unique mechanism of action and flexibility with formulation and route of administration (including oral), positions Matinas’ LNC technology to potentially become the preferred next-generation intracellular drug delivery vehicle with distinct advantages over both lipid nanoparticles and viral vectors.

MEPSGEN, a biotech founded by YongTae Kim and Robert Langer in 2019, develops microengineered physiological systems so called organ-on-a-chip and uses the manufactured systems to study pathophysiological mechanisms of key diseases and screen new drug candidates for the treatment. With these studies supported by the technologies, the company has its own multiple new drug candidates, representative ones of which target Alzheimer's and brain tumors. The company specializes in developing and producing a 3D cell culture Microphysiological System platform and in discovering new therapeutics using nanomedicine technology. The products and services include improved accuracy in evaluating new drug candidates and reducing cost and duration of the development. The company carries out fundamental biological research and drug candidate test in an environment equipped with an organ-level function of connected human tissues, rather than studying in a traditional in-vitro experimental model using 2D cell culture, thereby enabling researchers to further verify the findings in more pathophysiologically relevant environments. MEPSGEN is holding many patents, patents pending, and numerous IP licenses in the biotechnology field. For more information visit www.mepsgen.com [ Industry ] Drug Discovery Drug Delivery Biotechnology [ Technology ] MEPS-X series - 3D Microphysiological System platforms MST-X series - Microvortex System, Nanoparticle manufacturing platform MG-X series – Nanomedicine, Biomimetic nanomaterial-based targeted drug delivery platforms

An R&D company focused on delivering innovative oncology and rare disease products to patients. Midatech has three platform technologies that are focused on improving bio-distribution and bio-delivery of medications in different ways – either via sustained delivery, targeted delivery, or direct delivery. These are: microspheres, saccaride nanoparticles, and gold nanoparticles.

Millennial Scientific manufactures sustainable separation and purification materials for the discovery, R&D, and manufacturing of pharmaceuticals and other chemicals. Our product portfolio includes the award-winning NanoPak-C all-carbon suite of chromatography products. These products enable economical (e.g., operation cost reduction) and better (e.g., yield improvement) performance. These products are available as bulk stationary phase media or packed in solid-phase extraction (SPE) and liquid chromatography columns. We are ISO 9001:2015, MBE (New York State (NYS)), and DBE (Metropolitan Transportation Authority (MTA)) certified.

Minerva Biotechnologies is a clinical stage biopharmaceutical company focused on developing immunotherapies for solid tumor cancers and cellular therapies for regenerative medicine. NCT04020575 is Minerva’s first-in-human trial of huMNC2-CAR44, a CAR T that targets the MUC1* growth factor receptor, for the treatment of metastatic breast cancers, 95% of which express a MUC1*. We are now expanding the current clinical trial to include our second CAR-T product that greatly increases persistence. The Company is rapidly accelerating its pipeline that includes next-gen CAR-T products, a straight antibody therapeutic and a small molecule therapeutic which are both for the treatment of cancer metastasis. Our track record of scientific breakthroughs is a testament to our visionary team and our collaborative culture. Join us in changing the world.

Molecular Instruments®(MI) designs and synthesizes kits for multiplexed, quantitative, high-resolution bioimaging in academic research, drug development, and clinical pathology and diagnostics. Their HCR™technology introduced the concept of conditional nucleic acid self-assembly — a foundational principle for the field of dynamic nucleic acid nanotechnology.

Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. Our core technology is derived from a plant virus, cowpea mosaic virus ("CPMV") which is non-infectious to humans or other animals but upon intratumoral administration is recognized by immune cells as foreign, eliciting a strong local innate immune response through the activation of multiple toll-like receptors (TLRs). In oncology indications, this TLR activation results in potent anti-tumor activity against the primary and distant tumor sites. Our lead candidate, MIE-101, has demonstrated broad and consistent antitumor activity as a single agent and when combined with standard treatments in multiple preclinical tumor models as well as in canine companion animals with advanced cancer. Research investigating this first-in-class intratumoral multi-TLR agonist continues to be supported by numerous publications and grant funding through our university collaborators. Our technology is also being investigated as part of a modular vaccine platform, utilizing CPMV as an immune stimulant linked with viral or cancer antigens. Data generated to date show promising results in both cancer and infectious disease preclinical vaccine models, including COVID-19. The vaccine research is currently being performed by one of our co-founders and is funded by the National Science Foundation with viral neutralization testing being performed by the National Institute of Allergy and Infectious Diseases (NIAID). ​ We are actively moving our unique technology platforms forward with the goal of filing an investigational new drug (IND) or similar application for oncology indications with the appropriate regulatory authorities to initiate clinical development of our lead candidates. Our goal is to advance our technology into veterinary and human studies in 2022.

Nammi Therapeutics, Inc. is an immuno-oncology company based in Los Angeles that is developing platforms and products that selectively activate anti-tumor immunity within the tumor microenvironment while minimizing systemic activation. By reducing systemic activation of the immune system, Nammi expects to improve safety and enhance the ability to combine multiple immune modulators. Nammi's lead product candidate, QXL138AM, is a Masked Immunocytokine (MIC) targeting a masked interferon to the tumor antigen, CD138. In addition to the MIC platform, Nammi has also developed a nanoparticle platform to deliver Immune Modulating Prodrugs (IMPs) using their Nammisome technology. Multiple Nammisome clinical candidates have also been selected for development.

Nanobiosym is a Massachusetts-based innovation engine and research institute that combines physics, biomedicine, and nanotechnology to create solutions for global health, energy, and environmental challenges. Founded by Dr. Anita Goel, the company operates through its commercial arm, Nanobiosym Diagnostics (NBSDx), focusing on portable diagnostic technologies. One of its key products is Gene-RADAR®, a portable platform that enables rapid and accurate detection of genetic fingerprints from pathogens, facilitating point-of-care diagnostics for diseases such as COVID-19. Nanobiosym also engages in research and incubation, developing technologies in mobile health, energy harvesting, and quantum computing. The Nanobiosym Global Initiative promotes public-private partnerships to deploy these technologies in underserved markets. Recognized as a top science innovator, Nanobiosym has received awards from various organizations, including DARPA and the XPRIZE Foundation. The company aims to democratize access to healthcare and sustainable solutions, targeting global health systems, governments, NGOs, and academic partners for collaboration.

Nanobiotix has been pioneering nanomedicine for more than 17 years to bring a different approach to medicine. Our therapeutic technologies are not based on biology or chemistry – they are based on physical principles at nanoscale. This paradigm shift has allowed us to discover novel approaches to improving treatment outcomes. Our company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. With this approach, our ambition is to benefit millions of patients who receive radiation therapy by improving the efficiency of radiation in tumor cells without increasing the dose received by surrounding healthy tissues. We believe that radiotherapy combined with NBTXR3 can become a new standard of care in the treatment of cancer. By viewing the human body through the lens of physics a new realm of possibilities has emerged.

Applied NanoBiology™ is the intersection between nanotechnology and biology. Artoss scientists apply their knowledge of physics and biology to create new nanostructured biomaterials for bone repair. This represents A New Dimension in Bone Repair™. Artoss, Inc. currently distributes NanoBone® advanced bone graft products in the United States. NanoBone Granules and NanoBone SBX Putty have been used successfully in 400,000 cases over the past ten years in Europe and US. NanoBone performs as well as the competing gold standards for bone grafting, with lower complications than autograft. Our German partner, Artoss GmbH, has multiple issued and pending patents to protect the technology. Artoss intends to develop and introduce multiple proprietary forms of NanoBone to address specific clinical needs. This includes the use of NanoBone as an implant coating to improve osteointegration of joint replacements and spinal fusion implants.

nanoComposix is a world leading manufacturer of precisely engineered and highly characterized nanoparticles. Our mission is to help our customers bring nanotechnology-enabled products to market. Our multi-disciplinary technical teams provide rapid prototyping, characterization, integration, and scale-up solutions to accelerate R&D and commercialization for a wide variety of application areas including biodiagnostics, topical therapeutics, nanomedicine, antimicrobial coatings, and color engineering. Since 2004, nanoComposix has provided monodisperse and unagglomerated metal and metal-oxide nanomaterials to thousands of customers. Hundreds of different variants of material, size, shape, and surface are available as stock products and we have produced over 2000 custom core/shell, biofunctionalized, fluorescent, and magnetic nanocomposites to meet client specifications. All of our materials are supplied with certificates of analysis that include electron microscopy, hydrodynamic diameter, and optical data for each batch to guarantee products meet specifications. Contract manufacturing is performed on scales that range from small beakers to thousands of liters. Nanomaterials for medical devices and clinical trials are produced in our ISO 13485* and cGMP compliant cleanroom facility. By leveraging our unique library of nanomaterials, we aim to help our customers rapidly bring nanotechnology-enabled products from conception to commercialization. About Fortis Life Sciences: Fortis Life Sciences is a strategic platform providing capital, expertise, and operational resources enabling the growth and success of founder-led life sciences tools companies. Fortis Life Sciences was founded in 2020, with the vision of creating an exceptional life sciences company focused on offering world-class products coupled with a best-in-class customer experience. *For products manufactured under the scope of the ISO 13485 certification

Our mision is to improve the life of patients by designing new medicines that selectively target the cells affected by disease. With this approach we develope treatments that are more effective and have fewer adverse effects than classical drugs. We design our new drugs using state-of-the-art protein engineering and nanobiotechnology. First Project: New anti-metastatic drug Since cancer is the second cause of death worlwide, there is an urgent need for more effective and personalized treatments of tumors. Metastasis development is the main cause of patient death in most tumor types but the control of metastasis in cancer is still an unmet medical need. The current surgery-based approaches and conventional chemotherapy can be enhanced using new technologies. Our first project is a self-assembling protein nanoparticle that selectively kills metastatic cells. This nanoconjugate targets CXCR4 receptors which are over-expressed in metastatic cells of many types of cáncer. Preclinical results look very promising: in vivo results show that our drug-loaded nanoconjugate accumulates in primary tumor and metastatic foci with negible presence in liver, kidney, brain or other organs. The result is a significant decrease of the number of metastatic foci and very low toxicity on normal cells. Our focus now is to complete preclinical development in order to obtain approval for first-in-human trial.

Developing a technology platform that includes proprietary antibody-conjugated nanoparticles that are specifically adapted to antigen peptides that are only present in the bloodstream when the targeted disease is active.

Nanospectra Biosciences is a medical device company that specializes in nanomedicine for selective thermal ablation, with their lead product aimed at treating prostate cancer tissue.

Nanothericsprovides products addressing the field of magnetic nanoparticle research and applications. In particular we aim to be the number one supplier of products for nanoparticle heating applications utilizing AC field and solenoid coil principles.

Nanotools Bioscience is developing specialized nanotechnology-based cell culture microplates with “built-in” optical stimulation capabilities to provide dynamic optical stimulation of genetically intact cells during high-throughput screening drug discovery campaigns.

NanoValent Pharmaceuticals, Inc. is a pharmaceutical company developing a new nano-particle based TNS (Targeted NanoSpheres) technology to create and develop novel cancer therapies

NanoVation Therapeutics is a pioneer in the design and creation of lipid nanoparticles (LNPs) for nucleic acid delivery. The company’s LNP technologies aim to overcome the limitations of existing nucleic acid delivery approaches, including the ability to target tissues outside the liver (extrahepatic delivery). NanoVation’s lead technology is its proprietary long-circulating LNP (lcLNP™) platform, which enables functional nucleic acid delivery to extrahepatic cell types and has demonstrated an improved therapeutic index in preclinical studies. NanoVation partners with leading pharmaceutical and biotech companies develop genetic medicines for previously untreatable diseases. NTx is delivering tomorrow's genetic medicines, today. For more information, please visit nanovationtx.com.

NanoViricides, Inc. makesnanoviricides®. Nanoviricides are nanoparticles designed to protect cells from infection by acting as decoys. Virusesbind to nanoviricides instead of cell-surface receptors, gettrapped, and become neutralized.NanoViricides is working to developa treatment for COVID-19 using its nanoviricide®technology.

NANOVIS is a rapidly growing nanotechnology surface company. Our scientists use a broad portfolio of advanced nanotechnologies designed to improve spine, orthopedic, and dental surgical outcomes. nanoVIS Ti ™ Surface Technology received FDA nanotechnology designation and is cleared on commercially pure titanium and titanium alloy implants.

ONE STOP SOLUTION FOR DRUG DELIVERY Nanox focuses on the development of pharmaceutical products with complex drug delivery technologies like liposomes, pegylated liposomes, and microspheres depot with PLGA (polylactide - polyglycolide copolymers) formulations. Nanox owns worldwide rights for GM1-Nanomicelles, an innovative carrier for oncological drugs in preclinical stage currently being tested in neuro-oncology indications due its unique capacity to pass the Blood-Brain barrier

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The company has two product candidates in human trials, including NEXI-001 in acute myeloid leukemia, or AML; and NEXI-002 in multiple myeloma, or MM. NexImmune, Inc. was founded in 2011 and is headquartered in Gaithersburg, Maryland.

NH TherAguix is a biotech company registered at RCS Grenoble and based 19, Chemin des prés, 38240 Meylan

We’re focused on using our proven vaccine technology to protect health by developing our R&D assets and establishing partnerships. We stand strong against infectious diseases and viral threats—our science grounds us, our technology pushes us forward, our commitment inspires us to achieve our mission of ensuring broad access to our vaccines. It’s more than our job. It’s our passion. Our Novavax Social Community Guidelines: https://www.novavax.com/social-media-community-guidelines

NVIGEN is a nanobiotechnology company that specializes in multifunctional nanoparticles for biomedical applications through their proprietary NID platform.

At Oceanit, a rule-breaking practice of Intellectual Anarchy™ produces disruptive innovation, as we consistently discover the edges of thinking and create breakthroughs in science, engineering, and technology to change the world. Our teams create innovative solutions through engineering consulting in civil, coastal, and environmental engineering; information systems consulting; management consulting, including Design Thinking and scientific research. Empowering our teams to practice transdisciplinary thinking allows for extraordinary problem-solving across disciplinary boundaries. Our teams morph together and apart, aligning the best experts in each discipline to solve some of the world’s toughest problems Here at Oceanit, our mission is to create value from... Innovation through engineering and scientific excellence... produced in an environment where elements of such work and play are indistinguishable. We are proud of what we’ve created and what lies ahead. We are Oceanit.

OPTIMUM THERAPEUTICS LIMITED is a biotechnology company that focuses on developing nanomedicines for cancer therapy, targeting cellular and molecular levels.

Develop DNA nanostructures

Parvus Therapeutics Inc. is a privately held biopharmaceutical company developing Navacims™, a platform technology based on foundational research published in 2016 (Nature 530:434), to treat autoimmune diseases. Parvus’ mission is to shift the treatment paradigm toward Navacim-directed immune regulation, avoiding non-specific immune suppression associated with current therapies. Parvus’ innovative approach has the potential to benefit millions of patients suffering from debilitating autoimmune diseases and other chronic inflammatory conditions. Parvus is advancing a pipeline of proprietary drug candidates for multiple autoimmune indications through preclinical development and into the clinical. Parvus’ leadership team is experienced in successful drug discovery, development, manufacturing, regulatory approval, and commercialization.

PDS Biotech is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies based on the Versamune® platform, a T-cell activating technology, designed to harness the power of the body's immune system in the fight against cancer and infectious disease.

PDX Pharmaceuticals is an IND-enabling stage biopharmaceutical company. We develop novel combination and immunotherapies to treat cancer by bringing complementary biological pathways together to achieve synergistic clinical benefit. Our therapeutic candidates bridge the innate and adaptive immune systems by generating profound CD8+ T cell production. Our pipelines are patented AIRISE (Augmenting Immune Responses and Inhibiting the Suppressive Environment of Tumors) and ARAC (Antigen Release Agent and Checkpoint Inhibitor) pipelines that generate anti-tumor immunity when given locally (AIRISE) or systemically (ARAC) by relying on patient' s own tumor in situ as the source of antigens.

Phitonex uses a DNA nanotechnology platform to create highly customizable, deterministic fluorescent nanoparticles called Phitons.™

Phosphorex provides drug delivery solutions to the pharmaceutical and biopharmaceutical industries, which include drug encapsulation, nanosizing, microemulsion, and surface functionalization and coating. Following is a brief summary of our expertise: • Microencapsulation/nanoencapsulation of small molecule active pharmaceutical ingredients (APIs) or biomolecules into biodegradable microspheres or nanoparticles enables controlled or sustained drug release, protecting APIs from premature degradation as well as increasing circulation time and targeted drug delivery. • Nanosizing can help you transform poorly soluble APIs with low bioavailability into nanocrystals that can be delivered more easily with enhanced solubility and bioavailability. • Microemulsion, in which a poorly soluble API is dissolved in oil and micro-emulsified into an aqueous media to form a homogeneous mix. • Surface functionalization and coating in which we attach a biological entity on the surface of drug loaded microspheres or nanoparticles via either covalent bonding or physical adsorption to enable cell entry, brain-blood barrier crossing, and targeted drug delivery. The services we provide apply to all stages of your drug development efforts. Whether you are testing a new idea, conducting animal studies, or moving to clinical studies, we can assist. With our fully integrated cGMP system, we can assure you that our processes are completely reproducible and scalable. Please visit www.phosphorex.com for more information.

Photon Biosciences' core technology is a new ultrasensitive detection platform that combines bioengineered proteins with a uniquein vivobiomineralization process that results in a number of different genetically expressible luminescent bionanoparticles that are non-bleaching and non-blinking with luminescence intensities that rivals and surpasses many fluorescent organic molecules. The excitation and emission wavelengths of these expressible bionanoparticles can be tuned with the composition of the mineralization process and span much of the visible and near infrared regions of the electromagnetic spectrum. Because of its unique photophysical properties, PBS® has been developed into new ultrasensitive probes for biomolecular research, detection technologies, and cellular imaging.The company is developing a test to detect contamination in donated platelets.

POP Biotechnologies, Inc is Buffalo NY biotechnology company focused on the development of innovative biomedical solutions harnessing next generation nanotechnologies.

Precision NanoSystems, now part of Cytiva, is a global leader in ushering in the next wave of genomic medicines in infectious diseases, cancer, and rare diseases. We work with the world's leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genomic medicines.

Privo Technologies is a privately funded, Phase III oncology company that spun out of the world-renowned Langer Laboratory at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts, USA. Privo is developing a novel, nanotechnology-based drug delivery platform capable of local and systemic delivery of a constant, controlled therapeutic dose through the mucosa. This approach eliminates needles, avoids stomach acids, can significantly reduce toxic side effects of drugs and allows for higher dosing where the drugs can be most effective – all of which improve patient outcomes and compliance. Privo was founded by Manijeh Goldberg who is a seasoned executive with over 25 years of experience in the medical industry as an executive leader and a scientist in large and small start-up companies, one of which (Epicon) was acquired for $475M. Her 12 years of large company experience includes working for HP medical and Siemens Medical Systems. Manijeh's MBA from MIT and MS from Harvard Medical School led to her working with Professor Robert Langer. Professor Langer has global expertise in nanotechnology and drug delivery and is now an advisor to Privo. Privo is focused on dramatically improving human health through its novel and proprietary Mucosal Delivery Particle (MDP) platform. Privo's platform has both small and large molecule applications. The technologies used in Privo's platform have won awards and significant grants from the FDA and NIH.

QurCan Therapeutics (formerly Nanology Labs Inc) is a biotechnology company using advanced nanoparticle drug-delivery technology to unleash the immense potential of next-generation biological and genetic medicine and deliver life-changing therapeutics. QurCan's next generation nanoparticle platform, TERP, enables tissue-selective delivery of nucleotides and biological therapeutics to extra-hepatic sites, including brain and spleen. TERP technology is a breakthrough technology with the great potential to deliver a new era of disease-modifying genetic medicine that will make a difference to patients with a wide range of unmet medical needs.

Qurin Diagnostics is developing diagnostic technology platform for noninvasive testing. Current developments are focused on advanced biochip technology suitable for multiple biological and biomedical applications.

RadioNano Therapeutics, a venture company, was established with the support of Kyoto University Innovation Capital Co. Ltd. for the social implementation of Boron Neutron Capture Therapy (BNCT) using highly hydrophilic boron-containing inorganic nanoparticles developed by Professor Naoki Komatsu of the Graduate School of Human and Environmental Studies, Kyoto University and Professor Minoru Suzuki of the Institute for Composite Nuclear Science, Kyoto University.

Radiopharm Theranostics is developing a world-class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic applications. The company is focused on innovating the way we see and treat cancer, with a particular emphasis on HER-2 cancers. Radiopharm Theranostics has a strong team of executives and board members, and is actively engaged in investor relations and corporate governance. The company has also launched a joint venture with MD Anderson to focus on novel radiopharmaceuticals.

Red Arrow Therapeutics, Inc. is a biotechnology company focusing on developing new technologies that can turn "cold" tumors into inflamed "hot" tumors. Red Arrow Therapeutics' lead product candidate, RA-001, a pH-activated polymer micelle loaded with IL-12, is designed to release fully active IL-12 upon sensing intratumoral pH to safely potentiate immunotherapy. In the current pre-clinical data, RA-001 exhibits strong anti-tumor immunity in various tumor models. Furthermore, RA-001 shows high efficacy as monotherapy and in combination with immune checkpoint inhibitors.

Revalesio is a clinical-stage pharmaceutical company committed to creating treatments for neurological diseases and conditions that lack adequate therapeutic options. Our therapies address cellular imbalances related to mitochondrial dysfunction and thereby modulate the immune response. They have been shown to protect neurons in models of chronic neurological diseases and improve recovery in acute neurological injury. We are partnering with internationally renowned scientists in biomedical research in a concerted effort to improve the lives of millions.

RS Research is a clinical-stage biotechnology start-up based in Epalinges, Switzerland, with an additional location in Istanbul, Turkey. Founded in 2015, the company specializes in discovering and developing smart nanomedicines aimed at targeted cancer therapy. The company provides services for pre-clinical studies, utilizing its expertise in innovative drug delivery platforms to support the development of nanomedicines. RS Research's product pipeline includes smart nanomedicines like Sagitta® and Dui, which enhance the therapeutic index and manufacturability of treatments, and RS-0139, a drug candidate currently in Phase I clinical trials that targets tumors with specific receptors. RS Research is committed to advancing its technologies through research and development, as evidenced by its presentations at international conferences. The leadership team includes Co-Founder and Chief Scientific Officer Rana Sanyal and Co-Founder and Chief Operating Officer Sena Nomak.

Sable Therapeutics is a biotherapeutics company leveraging novel scientific insights to aid in fat treatment. Our nanomedicine based delivery platform, which can be used with other fat treatments, is engineered to target fat and deliver drug payload. Sable is led by a world-class and experienced management team, including a leading fat metabolism researcher at Columbia University Medical Center, that is passionate about executing this vision.

Shape Biopharmaceuticals is a next-generation immunotherapy developer. With our ambitious team and network, we strive to create a new class of immunotherapeutic drugs for chronic human diseases with high unmet treatment needs, leveraging computational epitope-specific antigen design and next-generation nanoparticle engineering.

Shaperon is a clinical stage biotech company developing novel inflammasome inhibitors(small molecule). Its unique mechanism of action of GPCR-regulated P2X7 inhibition suppresses a broad spectrum of inflammatory cytokines including IL-1β, IL-18, IL-6, and TNF-α, etc. by controlling both priming and activation phase of inflammasome, whereas conventional approaches are designed to suppress only the activation phase. With this unique and novel modality which is best suited to address complex immune-mediated inflammatory disorders, we are currently developing multiple clinical programs in atopic dermatitis, cytokine release syndrome, Alzheimer’s disease, ulcerative colitis, NASH, etc. In addition to inflammasome R&D programs, Shaperon has anti-viral, anti-cancer nanobody therapeutics. Shaperon’s proprietary immunized nanobody libraries combined with high throughput screening and in vitro/in vivo system enable us to fast forward the realization of advantages of Nanobodies over conventional antibody-based medicines. We currently developing multi-valent, multi-specific Nanobodies in multiple delivery forms in oncology and viral infection diseases.

At SK bioscience, we work everyday to promote human health from prevetion to cure. We have successfully developed South Korea's first COVID-19 vaccine, 'SKYCovione' through global cooperation with the Bill & Melinda Gates Foundation, CEPI, GSK, etc., and a universal vaccine to prevent ‘Sarbecovirus.’ We have also developed the world's first quadrivalent cell-cultured influenza vaccine, SKYCellflu with obtaining WHO PQ (Pre-qualification) certification in 2019 followed by developing SKYZoster, the world's second shingles vaccine, and SkyVaricella, the world's second WHO PQ-certified chickenpox vaccine. We are expanding our R&D pipeline through global partnerships with public and private institutions, and is planning to commercialize a pneumococcal conjugate vaccine, cervical cancer vaccine, typhoid conjugate vaccine, and rotavirus vaccine. In addition, SK bioscience signed a CMO contract to manufacture AstraZeneca's COVID-19 vaccine from drug substance to drug product at L-House, SK bioscience’s vaccine manufacturing plant, and contributed to the early prevention of COVID-19, recognized as a global hub for vaccine manufacturing. Based on innovative technology, all pf our colleagues are trying to achieve the company’s mission, ‘We promote human health, from prevention to cure.’ To meet social expectations, SK bioscience will build trust as a global innovative partner of vaccine and biotech so that all stakeholders, including employees, customers, shareholders, and local communities, could be proud and happy.

Stata DX is a developer of a disease management eRapid technology designed to implement custom biomarker panels for clinical studies.

SUPERBRANCHE : Nanomedicine as a breakthrough to treat cancer We bring answers to the following issue: intratumoral injection of nanomaterials implying both accessibility and detection of the tumor beforehand. We position ourselves as a producer dedicated to the synthesis of architectured nanomaterials as simple as possible and of controlled size. Our modular technology platform presents both therapeutic and diagnosis applications. It consists in a magnetic nanoparticle coated by a tailor made branched architecture. Thanks to their optimized shape and stability, our compounds are well tolerated and can be administered intravenously, thus helping to the early detection and treatment of metastases. The main advantage of the SUPERBRANCHE technology stem from our specific processes and synthesis know-how which are at the heart of our innovations. Superbranche is a Biotechnology company characterized by two main activities: - the sale of dendrimers and nanoparticles as research products to any laboratory in the field of nanomedicine - conducting development partnerships to bring to the clinics targeted diagnostic and image-guided therapy nanomaterials based on its proprietary technology.

Surginex is a company that operates a drug discovery platform intended to develop next-generation bio platforms and new drugs. The company specializes in 361 HCT/P allografts and is committed to turning innovative scientific research into practical medical solutions.

A new treatment for cancer

TherapyX Inc. is changing the future of pharmaceuticals using revolutionary technology. They encapsulate large biological molecules in an orally ingestible form, allowing these molecules to remain fully intact.

At TLC, we are dedicated to the development of novel nanomedicines that maximize the potential of our proprietary LipAD® lipid-assembled delivery system to enable sustained release and/or targeted deliveries that reduce toxicity and improve efficacy. We focus on creating new therapies in the areas of pain management, oncology, ophthalmology and infectious diseases. Effective drug development is a challenging and complex effort that requires the coordinated talents of many skilled individuals working as a team. If you believe in the potential for new medicines to improve quality of life and bring hope to those in need, we invite you to join us. We welcome applications from all over the globe.

Topas Therapeutics is a clinical-stage biotechnology company transforming the field of immune tolerance with a novel antigen-specific and targeted nanoparticle technology. Our antigen-coupled nanoparticle platform harnesses the tolerogenic power of the liver to treat autoimmune diseases. Our proprietary Topas Particles Conjugates target liver sinusoidal endothelial cells, a specific type of antigen-presenting cells highly effective at inducing T cell tolerance. With a technology adjustable to a broad spectrum of disease-relevant antigens, we have established a growing and advanced clinical pipeline to induce systemic tolerance. To learn more visit https://topas-therapeutics.com/

We will create immunotherapy using nanotechnology as a new treatment option for intractable cancers and viral infections.Uniting Immunity and Nanotechnology for Fighting Cancer and Infectious Diseases

Vader Environmental Nanotech is using biotechnology to fight chemical contamination such as PFAS and remove these contaminants from the environment. They have developed a high throughput screening technology to identify microbes that can use harmful chemicals as a food source.

At the Wyss Institute, we leverage recent insights into how Nature builds, controls and manufactures to develop new engineering innovations - a new field of research we call Biologically Inspired Engineering. Our scientists, engineers and clinicians, who come from Harvard's Schools of Medicine, Engineering, Arts & Sciences, Design, and Education as well as 12 collaborating academic institutions and hospitals, work alongside staff with industrial experience in product development to engineer transformative solutions to some of the world’s greatest problems. By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.

Zafrens is a therapeutics company pioneering an ultra-high throughput platform to isolate, culture, image, and sequence millions of cells per day. The proprietary platform allows for full characterization of diverse cell populations, as well as directly correlating molecular profiles (DNA, RNA, protein) to cell phenotype and function. The company’s mission is to unlock the full story of every cell to accelerate drug discovery.

Zeda is a leading technology solutions company. Our objective is to better lives by investing in cutting-edge technologies, innovative companies, and groundbreaking ideas. Our foundation combines expertise from diverse industries, including AM, nanotech, precision manufacturing, and incubating new ideas. From life-changing medical devices to the foremost advancements in space, our mission is to build it all better together.

Based in South Florida, ZEO ScientifiX™ is a publicly traded biotechnology company committed to the research, development and manufacture of new biologic medicine, with a focus on current and potential regenerative therapeutics. ZEO ScientifiX™ is the leading, fully integrated Biologic Medicine Company. Our mission is to transform regenerative medicine through the development of novel nano-technologies and to become the health care incubator for the next generation of biologic medicines.

Zystein offers alternativehealthcare products made only from all-natural materials. They also offer reagents that canencapsulateactive ingredients, drugs, and vaccines.